Sexual functioning in breast cancer survivors.
BACKGROUND
A growing body of evidence suggests that sexual dysfunction may be among the more common and distressing symptoms experienced by breast cancer survivors.


METHODS
This report reviews studies in which sexual functioning in breast cancer survivors has been investigated. Included are reports on the prevalence and nature of sexual difficulties, the relationship between specific breast cancer treatments and sexual difficulties, and the treatment of sexual dysfunction following completion of breast cancer treatment.


RESULTS
A review of the literature suggests a wide range of rates for the prevalence of sexual problems in breast cancer survivors. Factors that may affect prevalence rates include the methods used to determine prevalence and the demographic and medical characteristics of the patients studied. With regard to treatment effects, evidence suggests that breast cancer patients who undergo chemotherapy are at high risk for sexual dysfunction after treatment. In contrast, there is little evidence of a link between type of surgical treatment (eg, lumpectomy vs mastectomy) or treatment with tamoxifen and sexual functioning outcomes.


CONCLUSIONS
A growing body of evidence suggests that sexual problems can be a long-term side effect of breast cancer treatment. Oncology professionals should initiate communication about sexual difficulties, perform comprehensive assessments, and educate and counsel patients about the management of these difficulties.
Thors
C L
CL
Psychosocial and Palliative Care Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Broeckel
J A
JA
Jacobsen
P B
PB
D000970:Antineoplastic Agents / Q000009:adverse effects; D001943:Breast Neoplasms / Q000628:therapy*; D005260:Female; D006801:Humans; D008408:Mastectomy / Q000009:adverse effects; D015995:Prevalence; D012735:Sexual Dysfunction, Physiological / Q000453:epidemiology / Q000209:etiology / Q000628:therapy; D017741:Survivors
D000970:Antineoplastic Agents